Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Breast Neoplasms

Neoplasm Metastasis

Recurrence

Breast Diseases

Skin Diseases

Patients in this arm will be treated by completion axillary clearance after a sentinel node biopsy showing 1-2 nodes with macrometastasis

Patients in this arm will not undergo further axillary surgery after a sentinel node biopsy showing 1-2 nodes with macrometastasis

The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis

Omission of axillary clearance

Jana de Boniface, PhD

Jan Frisell, Professor

Leif Bergkvist, Professor

Yvette Andersson, PhD

Lisa Ryden, Professor

Malin Sund, Professor

Olofsson Roger, PhD

Johan Ahlgren, PhD

Dan Lundstedt, PhD

Peer Christiansen, Professor

Tove Tvedskov Filtenborg, MD

Michalis Kontos, PhD

Birgitte Offersen, Professor

Thorsten Kühn, Professor

Toralf Reimer, Professor

Oreste Gentilini

Roland Reitsamer

Since the introduction of sentinel node biopsy in breast cancer, it has become clear that its use is reliable and reproducible. Today, it is clinical routine to not remove further lymph nodes from the axilla (arm pit) in case the sentinel node (which is the first lymph node/s reached by lymphatic flow from the breast) is free of tumor deposits. It is also routine to leave remaining lymph nodes behind in case the sentinel node contains a minimal cluster of tumor cells, called isolated tumor cells (formerly submicrometastasis). Even in slightly larger tumor deposits, so called micrometastasis (up to 2 mm in size), it has been shown that a completion axillary clearance (removal of further lymph nodes from the arm pit) does not contribute to a better survival. Data from a randomized study indicate that it seems safe to omit axillary clearance even if the sentinel node biopsy shows up to 2 nodes with tumor deposits over 2 mm in size (macrometastasis). These studies have changed clinical practice in many countries, however, it is still debated whether it is safe to omit axillary clearance in the case of sentinel node macrometastasis due to under-recruitment in the aforementioned study. The rationale for omitting extensive axillary surgery is the avoidance of postoperative morbidity such as arm lymphedema, loss of sensation, pain and swelling.

The hypothesis is that refraining from axillary clearance in breast cancer patients with 1-2 sentinel nodes with macrometastasis will not worsen breast cancer-specific survival by more than a maximum of 2.5% after 5 years.

This study is a prospective international randomized trial including 3500 patients.

Breast cancer patients without signs of axillary nodal involvement will be eligible for sentinel node biopsy. Those who are found to have up to two sentinel node containing macrometastasis will be informed about this trial Those wishing to participate will be randomized to either undergo further axillary surgery (clearance) or not. Outcome measures are breast cancer-specific survival, disease-free survival, axillary recurrence rate and overall survival.

Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.

Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node

death due to breast cancer in both arms measured at a median follow-up of 5, 10 and 15 years

Breast cancer recurrence rate in both arms after a median follow-up of 5, 10 and 15 years

The rate of axillary relapse in specific after a median follow-up of 5, 10 and 15 years

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.	NCT02240472	Breast Cancer	Omission of axi...	18 Years -	Karolinska Institutet
Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.	NCT02240472	Breast Cancer	Omission of axi...	18 Years -	Karolinska Institutet

Spots Global Cancer Trial Database for sentinel node biopsy, lymph node metastasis, survival